Tumor Immune Microenvironment Heterogeneity at the Invasion Front and Tumor Center in Oral Squamous Cell Carcinoma as a Perspective of Managing This Cancer Entity.
OSCC
head and neck cancer
immune microenvironment
immunohistochemistry
pathology
spatial distribution
topology
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Feb 2023
20 Feb 2023
Historique:
received:
15
12
2022
revised:
13
02
2023
accepted:
17
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Evaluating the tumor microenvironment and its influence on clinical management and therapy response is becoming increasingly important. However, only a few studies deal with the spatial distribution of immune cells within the tumor. This study aimed to describe the topology of immune cells in the microenvironment of oral squamous cell carcinoma (OSCC) sectioned by tumor invasion front and tumor center and to test their prognostic relevance regarding patient survival. A total of 55 OSCC patient specimens were collected retrospectively. The cancer tissue was immunohistochemically stained using an automated tissue stainer Ventana Benchmark Ultra (Roche) and analyzed using discrete expression marker profiles on immune cells. We investigated CD4+ lymphocytes, CD8+ lymphocytes, CD68+ macrophages, CD163+ macrophages, and M1 macrophages regarding their spatial distribution. The statistical analysis revealed that the quantity and distribution of CD4+ ( Our results show two distinct immune microenvironments of the tumor center compared to the invasion front. Future studies are needed to explore how these results can be leveraged to improve patient therapy and outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Evaluating the tumor microenvironment and its influence on clinical management and therapy response is becoming increasingly important. However, only a few studies deal with the spatial distribution of immune cells within the tumor. This study aimed to describe the topology of immune cells in the microenvironment of oral squamous cell carcinoma (OSCC) sectioned by tumor invasion front and tumor center and to test their prognostic relevance regarding patient survival.
METHODS
METHODS
A total of 55 OSCC patient specimens were collected retrospectively. The cancer tissue was immunohistochemically stained using an automated tissue stainer Ventana Benchmark Ultra (Roche) and analyzed using discrete expression marker profiles on immune cells. We investigated CD4+ lymphocytes, CD8+ lymphocytes, CD68+ macrophages, CD163+ macrophages, and M1 macrophages regarding their spatial distribution.
RESULTS
RESULTS
The statistical analysis revealed that the quantity and distribution of CD4+ (
CONCLUSION
CONCLUSIONS
Our results show two distinct immune microenvironments of the tumor center compared to the invasion front. Future studies are needed to explore how these results can be leveraged to improve patient therapy and outcome.
Identifiants
pubmed: 36836239
pii: jcm12041704
doi: 10.3390/jcm12041704
pmc: PMC9958892
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oral Oncol. 2019 Jun;93:66-75
pubmed: 31109698
Oncoimmunology. 2022 May 5;11(1):2066767
pubmed: 35558160
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
Cancer Res. 2020 Oct 15;80(20):4414-4425
pubmed: 32699134
Nat Commun. 2019 Sep 2;10(1):3928
pubmed: 31477692
Iran J Otorhinolaryngol. 2021 Jul;33(117):191-200
pubmed: 34395318
Clin Cancer Res. 2014 Apr 1;20(7):1891-9
pubmed: 24691640
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Head Neck Pathol. 2020 Sep;14(3):689-700
pubmed: 31749124
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Laryngoscope. 2021 Nov;131(11):2512-2518
pubmed: 33955550
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
J Oral Pathol Med. 2018 Apr;47(4):359-367
pubmed: 29469989
Arch Pharm Res. 2016 Nov;39(11):1588-1596
pubmed: 27562774
Cancer. 2013 Dec 15;119(24):4242-8
pubmed: 24114787
Ann Transl Med. 2019 Jul;7(Suppl 3):S75
pubmed: 31576284
Strahlenther Onkol. 2023 Feb;199(2):121-130
pubmed: 36251031
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Pathobiology. 2021;88(5):327-337
pubmed: 33965948
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33931472
Microcirculation. 2016 Feb;23(2):95-121
pubmed: 26614117
Acta Otolaryngol. 2020 Mar;140(3):246-248
pubmed: 32022615
Oral Oncol. 2021 Oct;121:105451
pubmed: 34329869
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
PLoS One. 2022 May 27;17(5):e0269136
pubmed: 35622885
Br J Cancer. 2019 Apr;120(7):714-727
pubmed: 30808992
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Oral Oncol. 2015 Jan;51(1):90-5
pubmed: 25283344
Adv Radiat Oncol. 2018 Oct 23;3(4):520-526
pubmed: 30370351
Oncology. 2021;99(7):464-470
pubmed: 33789303
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Oncol. 2012;2012:608406
pubmed: 22927846
Cancer Immunol Res. 2020 Sep;8(9):1122-1138
pubmed: 32665262
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 May;109(5):744-52
pubmed: 20303300
Front Oncol. 2021 Mar 18;11:611115
pubmed: 33816242
J Pers Med. 2022 May 07;12(5):
pubmed: 35629179
EClinicalMedicine. 2021 Sep 16;41:101134
pubmed: 34585125
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Clin Cancer Res. 2021 Jan 15;27(2):632-644
pubmed: 33109740
Head Neck Pathol. 2017 Sep;11(3):354-363
pubmed: 28032290
CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21
pubmed: 26215712
Biomedicines. 2022 Jul 28;10(8):
pubmed: 36009369